Renaissance Capital logo

Apexigen (Brookline Capital Acquisition) Priced, Nasdaq: APGN

Blank check company formed by Brookline Capital Markets targeting a life science business (completed 8/1/2022).

Industry: SPAC

First Day Return: +2.3%

Industry: SPAC

We are a newly organized blank check company. While we may pursue an acquisition opportunity in any industry or sector, we intend to capitalize on our management team’s differentiated ability to source, acquire and manage a business in the life sciences industry. Our sponsor is an affiliate of Brookline Capital Markets, a division of Arcadia Securities, a boutique investment bank with experience providing capital markets and advisory services to public and private life sciences companies, blank check companies (working with management teams during the IPO process, and later in the course of their initial business combinations) and other emerging growth enterprises. We believe that our management team is well positioned to identify opportunities in the life sciences sector. Through our relationship with Brookline we have extensive proprietary deal flow from our network of venture capital firms, private and public corporate clients, investment banking partners and existing investor referrals, essential in sourcing and vetting potential business combinations. Given our profile and dedicated industry approach, we anticipate that potential target businesses may also be brought to our attention from various unaffiliated sources.
more less

Apexigen (Brookline Capital Acquisition) (APGN) Performance